HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Parlux gets conditional listing

This article was originally published in The Rose Sheet

Executive Summary

Nasdaq Listing Qualifications Panel grants Parlux's request for continued listing on the stock market subject to the condition that Parlux files its delayed financials on or before March 31, company states March 12. The firm, which presented before the panel earlier this month, has yet to report fiscal year 2006 Q2 and Q3 results (1"The Rose Sheet" March 5, 2007, In Brief). Nasdaq said it will immediately suspend Parlux from trading on the market and may delist its common stock if the firm misses the deadline. Parlux attributes the delay to an ongoing investigation by its audit committee, noting that the company cannot file its reports until the investigation is complete. The committee is investigating a class action suit alleging Parlux "improperly recognized revenue on sales to related parties and failed to comply with SEC disclosure rules." The firm plans to ask the Nasdaq Listing and Hearing Review Council to weigh in on the panel's March 31 deadline...

Nasdaq Listing Qualifications Panel grants Parlux's request for continued listing on the stock market subject to the condition that Parlux files its delayed financials on or before March 31, company states March 12. The firm, which presented before the panel earlier this month, has yet to report fiscal year 2006 Q2 and Q3 results (1 'The Rose Sheet' March 5, 2007, In Brief). Nasdaq said it will immediately suspend Parlux from trading on the market and may delist its common stock if the firm misses the deadline. Parlux attributes the delay to an ongoing investigation by its audit committee, noting that the company cannot file its reports until the investigation is complete. The committee is investigating a class action suit alleging Parlux "improperly recognized revenue on sales to related parties and failed to comply with SEC disclosure rules." The firm plans to ask the Nasdaq Listing and Hearing Review Council to weigh in on the panel's March 31 deadline....

Latest Headlines
See All
UsernamePublicRestriction

Register

RS014599

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel